Dailypharm Live Search Close

Hanmi leads the prescription market for 7 consecutive years

By Chon, Seung-Hyun | translator Alice Kang

25.01.15 05:20:29

가나다라 0
Outpatient prescription performance of pharmaceutical companies in 2024... Sales of Hanmi Pharmaceutical's new combination drugs surge

Chong Kun Dang remains in 2nd place for 7 consecutive years...Dawoong, Yuhan, HK Inno.N show strong growth supported by their new drugs

Daewon Pharmaceutical’s prescriptions have increased 68% in 5 years, supported by the good performance of its cold drugs

Hanmi Pharmaceutical has led the domestic outpatient prescription market for 7 consecutive years. The company has solidified its lead in the market fueled by the strong performance of the new combination drugs it developed with its R&D capabilities. Large pharmaceutical companies such as Chong Kun Dang, Daewoong Pharmaceutical, Yuhan Corp, HK Inno.N, and Daewon Pharm showed high growth due to the strong performance of their flagship drugs that include new drugs and new combination drugs.

According to drug research institute UBIST on the 15th, Hanmi Pharmaceutical posted the highest prescription sales among domestic and foreign pharmaceutical companies in the outpatient prescription market last year, up 7.1

Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)